PharVision Advisers’s Goldman Sachs BDC GSBD Stock Holding History

PharVision Advisers’s Portfolio GSBD Stock Details GSBD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-11,536	Closed	-$140K	–	373
2024 Q4	$140K	Buy	+11,536	New	+$151K	0.12%	352

Other funds holding GSBD

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

VanEck Associates New York $164B AUM 112.45% 1-Year Est. Return

GAM

Generali Asset Management Trieste, Italy $5.53B AUM 35.1% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return

PharVision Advisers's GSBD Position: Q1 2025 in Review

PharVision Advisers sold out of Goldman Sachs BDC (GSBD) in Q1 2025, closing a stake of 11,536 shares — an estimated $140K sold.

PharVision Advisers first reported a position in GSBD in Q4 2024 and held it in 1 quarter. The position peaked at $140K in Q4 2024. 227 funds tracked by Wall St. Rank hold GSBD as of Q1 2025.

PharVision Advisers reported no remaining Goldman Sachs BDC position as of Q1 2025 after selling out during the quarter.
PharVision Advisers sold 11,536 Goldman Sachs BDC shares in Q1 2025, an estimated $140K.
PharVision Advisers first reported a position in Goldman Sachs BDC in Q4 2024 and held it in 1 quarter.
PharVision Advisers's Goldman Sachs BDC position peaked at $140K in Q4 2024.
227 funds tracked by Wall St. Rank held Goldman Sachs BDC as of Q1 2025.

Based on PharVision Advisers's 13F filing for Q1 2025, filed 15 May 2025.